Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck's View On The Challenges Of Ebola Vaccination In The DRC

Executive Summary

With the latest Ebola outbreak threatening to spread across the Democratic Republic of Congo and beyond, efforts are being stepped up to vaccinate the at-risk population and health workers with Merck Sharp & Dohme’s experimental vaccine, V920. MSD’s Mel Kohn spoke to the Pink Sheet about the development of the vaccine, the experience gained from its use to date, and the difficulties involved in getting the vaccine to those who need it.

You may also be interested in...

Coronavirus Vaccine: How Hard Might Development Get? Look At Chikungunya

Epidemiology complicates field efficacy trials, but US FDA advisory committee members regretfully agree that data from non-human primate passive transfer studies is compelling but potentially insufficient for chikungunya vaccines.

Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019

The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.

Merck's Ebola Vaccine Will Get US FDA Decision Before March Review Deadline

Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts